Kovitz Investment Group Partners
ALNY icon

Kovitz Investment Group Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kovitz Investment Group Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$587K Sell
1,950
-8
-0.4% -$2.41K 0.01% 371
2026
Q1 		$648K Buy
1,958
+3
+0.2% +$1.02K 0.02% 372
2025
Q4 		$778K Sell
1,955
-652
-25% -$289K 0.02% 348
2025
Q3 		$1.19M Buy
2,607
+257
+11% +$105K ﹤0.01% 798
2025
Q2 		$766K Buy
2,350
+1
+0% +$277 ﹤0.01% 857
2025
Q1 		$634K Sell
2,349
-292
-11% -$75K ﹤0.01% 856
2024
Q4 		$622K Buy
2,641
+210
+9% +$55.2K ﹤0.01% 841
2024
Q3 		$579K Buy
+2,431
New +$633K ﹤0.01% 732

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kovitz Investment Group Partners's ALNY Position: Q2 2026 in Review

Kovitz Investment Group Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.41% in Q2 2026, selling an estimated $2.41K and leaving 1,950 shares worth $587K. The position accounts for 0.01% of the portfolio, ranked #371.

Kovitz Investment Group Partners first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.19M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Kovitz Investment Group Partners held 1,950 shares of Alnylam Pharmaceuticals worth $587K as of Q2 2026.
  • Kovitz Investment Group Partners sold 8 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.41K.
  • Alnylam Pharmaceuticals made up 0.01% of Kovitz Investment Group Partners's portfolio in Q2 2026, its #371 holding.
  • Kovitz Investment Group Partners first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Kovitz Investment Group Partners's Alnylam Pharmaceuticals position peaked at $1.19M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Kovitz Investment Group Partners's 13F filing for Q2 2026, filed 12 Aug 2026.